Kliogest

Norethisterone acetate and estradiol, the active ingredients in Kliogest, are a combined estrogen‑progestogen presented as an oral tablet for oral use. It is used for hormonal contraception and menstrual disorder management in women of reproductive age.

GNH USA supplies Kliogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kliogest, a combined estrogen‑progestogen, is indicated for conditions related to the reproductive hormonal axis.

Contraception: prevents pregnancy by suppressing ovulation and stabilising the endometrium. Menstrual disorder management: regulates cycle length and reduces abnormal uterine bleeding. Irregular bleeding: helps achieve a predictable bleeding pattern in women with cycle irregularities.

Kliogest may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of breast tissue. - Headache: transient tension‑type headaches. - Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Severe hypertension: sudden increase in blood pressure. - Liver dysfunction: abnormal liver enzymes or jaundice. - Allergic reactions: rash, itching, or swelling of face and throat. - Visual disturbances: sudden vision changes or loss.

Before prescribing Kliogest, clinicians should consider several safety factors.

Assess thrombotic risk: avoid in women with history of clotting disorders. Evaluate liver function: contraindicated in severe hepatic disease. Review smoking status: smoking >15 cigarettes/day increases cardiovascular risk. Counsel on missed doses: provide guidance on backup contraception. Monitor blood pressure: watch for hypertension development. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Kliogest can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Enzyme inducers (rifampicin, phenytoin, carbamazepine): may reduce contraceptive efficacy. - Selective estrogen receptor modulators (tamoxifen, raloxifene): may antagonise estrogen activity.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, itraconazole): may increase hormone plasma levels. - Antidepressants (SSRIs, SNRIs): may raise risk of bleeding. - Antihypertensives (beta‑blockers, ACE inhibitors): may require blood pressure monitoring.